The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

Verona Pharma plc (VRNA), a biopharmaceutical company, Tuesday announced that the company expects preliminary unaudited fourth ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...